3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Conditions
Carcinoma, Non-Small-Cell Lung
10
Neoplasm Metastasis
3
Lung Neoplasms
3
Adenocarcinoma of Lung
3
cMET-dysregulated Advanced Solid Tumors
2
Melanoma
2
Glioblastoma
2
cMET Dysegulation Advanced Solid Tumors
1
Sarcoma
1
Malignant Non-small Cell Neoplasm of Lung Stage IV
1
Liver Neoplasms
1
Kidney Neoplasms
1
Hepatic Impairment
1
Gliosarcoma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma
1
Bronchial Neoplasms
1
Advanced Solid Tumor
1
Interventions
Ipilimumab
114
pembrolizumab
95
Nivolumab
91
aldesleukin
86
Interleukin-2
57
Cyclophosphamide
54
Dacarbazine
52
Vemurafenib
39
trametinib
37
Temozolomide
37
incomplete Freund's adjuvant
35
fludarabine phosphate
35
sargramostim
32
dabrafenib
32
fludarabine
26
Bevacizumab
26
Paclitaxel
22
MART-1 Antigen
21
Granulocyte-Macrophage Colony-Stimulating Factor
21
montanide ISA 51
20
Interferon-alpha
20
Cisplatin
20
Carboplatin
19
Sorafenib
18
Introns
17
Biopsy
17
cobimetinib
16
Radiosurgery
16
atezolizumab
15
Radiotherapy
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Melanoma
×
capmatinib
×
Clear all
NCT03484923
2024-06-18
PLATforM
Novartis
Phase 2
Completed
196 enrolled
22 charts
NCT02159066
2024-03-05
LOGIC-2
Pfizer
Phase 2
Completed
158 enrolled
40 charts